Skip to main content
Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc. — Investor Relations & Filings

Ticker · LYRA ISIN · US55234L1052 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2024-04-19 Proxy Solicitation & In…
Country US United States of America
Listing US LYRA

About Lyra Therapeutics, Inc.

https://lyratherapeutics.com/

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company that develops and commercializes innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). The company's product candidates are long-acting, anti-inflammatory sinonasal implants designed to deliver medication directly to sinonasal tissues. This approach aims to provide a new, long-lasting treatment option for patients with this debilitating inflammatory disease, targeting tissues that are not easily accessible with conventional therapeutic methods.

Recent filings

Filing Released Lang Actions
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically titled as a "Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934." It includes detailed information about the Annual Meeting of Stockholders, including proposals to be voted on, board recommendations, and voting instructions. It also references the Annual Meeting date and the record date for shareholders entitled to vote. The document is not a report of voting results, nor is it an announcement of a report publication. It is not an earnings release, financial report, or management discussion. The content and form clearly identify it as a Proxy Solicitation & Information Statement, which is used to provide shareholders with information and solicit their votes for the meeting.
2024-04-19 English
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 15, 2024, reporting changes in the company's board of directors and committee appointments. It specifically details the resignation of a director and the appointment of a new member to the Audit Committee. There are no financial statements or earnings data, nor is it an announcement of a report publication. The content fits the category of Board/Management Information, which covers announcements of changes in the company's board or senior management.
2024-04-19 English
Regulatory Filings 2024
Regulatory Filings
2024-04-02 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 95% confidence The document is a letter from Lyra Therapeutics, Inc. addressed to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-3. It is a correspondence related to a securities registration process, specifically under the Securities Act of 1933. The document does not contain financial statements, detailed financial data, or report content. It is a formal request related to a capital raising process (registration statement effectiveness). Given the nature of the document as an update on a financing activity and the absence of financial results or report content, it fits best under Capital/Financing Update (CAP). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2024-03-28 English
Regulatory Filings 2024
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify the document as any specific filing type. According to the fallback rule, when a document does not fit any specific category due to lack of information, it should be classified as a Regulatory Filing (RNS). The document length is 15,000 characters, so it is not a short announcement but the content is unreadable.
2024-03-27 English
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans. It references registration of shares under specific award plans and incorporates by reference prior filings such as the Annual Report on Form 10-K and other SEC filings. The document is not a financial report, earnings release, or management discussion but a regulatory filing related to securities registration. It is a standalone SEC filing for registration purposes under the Securities Act of 1933, specifically a Form S-8. Therefore, it fits best under the category of Regulatory Filings (RNS), as it does not match other more specific categories like Annual Report or Capital/Financing Update.
2024-03-22 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.